Aligos Therapeutics (ALGS) Gains from Investment Securities (2019 - 2026)

Aligos Therapeutics (ALGS) has 5 years of Gains from Investment Securities data on file, last reported at -$3.4 million in Q1 2026.

• Quarterly Gains from Investment Securities rose 94.48% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (up 92.99% YoY) and the FY2025 annual result came in at -$60.2 million, down 230.46% from the prior year.
• Gains from Investment Securities retreated to -$3.4 million in Q1 2026, from -$1.2 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $62.1 million in Q4 2024 to a low of -$61.5 million in Q1 2025.
• A 3-year average of -$1.9 million and a median of -$1.2 million in 2025 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 3904.76% in 2025, down 527.84% in 2025.
• Tracing ALGS's Gains from Investment Securities over 3 years: stood at $62.1 million in 2024, then slumped by 101.95% to -$1.2 million in 2025, then plunged by 179.88% to -$3.4 million in 2026.
• The last three Gains from Investment Securities figures came in at -$3.4 million (Q1 2026), -$1.2 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.